ERBB2 and breast carcinoma: Survival rate varied by breast cancer subtype, with a median OS of 9.0 months (95% CI: 5.4–15.2) for HER2+ LM, 7.6 months (95% CI: 1.4–9.4) for HER2− LM, and 2.8 months (95% CI: 0.8–8.7) for TNBC LM.